Steglatro

Ertugliflozin (SGLT2 inhibitor) for diabetes mellitus management in cats. SGLT2 inhibitor (ertugliflozin). Mechanism: selective SGLT2 inhibition in renal proximal tubule → prevents glucose reabsorption → glucosuria → blood glucose reduction independently of insulin. Being evaluated for feline DM management. Oral administration. Key information Ertugliflozin — SGLT2 inhibitor (off-label equine/canine use). Monitor for electrolyte and volume changes. Ensure water access.

Oral solution (cats): administer once daily onto wet food using calibrated syringe. Administer with food to reduce GI adverse effects. Store at room temperature; protect from light. If a dose is missed Administer as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and resume the normal schedule. Never double up doses to make up for a missed one.

Genitourinary infections (UTI, mycotic). DKA risk. Polyuria/polydipsia. GI: vomiting, diarrhea. Volume depletion. Monitor for ketoacidosis.

For animals Cats only. Contraindicated in DKA. Monitor renal function, hydration status, and urine output. Not approved for use in food-producing animals. For people handling this medication Wash hands thoroughly with soap and water after handling. Avoid contact with eyes; if contact occurs, flush with water for 15 minutes and seek medical attention. Keep out of reach of children. If accidental ingestion occurs, contact Poison Control (1-800-222-1222). SGLT2 inhibitor — Wash hands thoroughly with soap and water after handling. after handling. Keep out of reach of children.

Contact your veterinarian. SGLT2 inhibitor overdose causes dehydration, electrolyte imbalances, and urinary tract changes.